EcoDrugPlus

Sodium Channel, Voltage Gated, Type Xii, Alpha A

Ensembl ID : ENSDARG00000090724
Gene Symbol: SCN12AA
3 Enzyme and pathways 5 Cross references
245 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSDARG00000014916
Gene Symbol: SLC10A2
5 Enzyme and pathways 5 Cross references
211 Possible Orthologues:

Solute Carrier Family 18 Member 2

Ensembl ID : ENSDARG00000015110
Gene Symbol: SLC18A2
10 Enzyme and pathways 4 Cross references
224 Possible Orthologues:

Solute Carrier Family 22 Member 6, Like

Ensembl ID : ENSDARG00000055523
Gene Symbol: SLC22A6L
5 Enzyme and pathways 5 Cross references
360 Possible Orthologues:

Solute Carrier Family 29 Member 1a

Ensembl ID : ENSDARG00000101289
Gene Symbol: SLC29A1A
5 Cross references
204 Possible Orthologues:

Solute Carrier Family 29 Member 1b

Ensembl ID : ENSDARG00000054447
Gene Symbol: SLC29A1B
4 Enzyme and pathways 5 Cross references
207 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSDARG00000013871
Gene Symbol: SLC5A1
6 Enzyme and pathways 5 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSDARG00000100919
Gene Symbol: SLC5A2
3 Enzyme and pathways 5 Cross references
199 Possible Orthologues:

Solute Carrier Family 6 Member 1a

Ensembl ID : ENSDARG00000045944
Gene Symbol: SLC6A1A
5 Cross references
204 Possible Orthologues:

Solute Carrier Family 6 Member 1b

Ensembl ID : ENSDARG00000039647
Gene Symbol: SLC6A1B
9 Enzyme and pathways 5 Cross references
209 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSDARG00000016141
Gene Symbol: SLC6A2
4 Enzyme and pathways 5 Cross references
204 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSDARG00000004219
Gene Symbol: SLC6A3
8 Enzyme and pathways 5 Cross references
167 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).